These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23833114)

  • 1. Bring me sunshine: EU drug companies make payments to doctors public.
    Jack A
    BMJ; 2013 Jul; 347():f4342. PubMed ID: 23833114
    [No Abstract]   [Full Text] [Related]  

  • 2. Letting the sunshine in: shining a new light on physician-industry relationships.
    Bruguera CM; Hirsch JA
    J Neurointerv Surg; 2010 Mar; 2(1):80-2. PubMed ID: 21990565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug companies will have to report all payments to US doctors from March 2014.
    Roehr B
    BMJ; 2013 Feb; 346():f826. PubMed ID: 23393117
    [No Abstract]   [Full Text] [Related]  

  • 4. Already feeling the heat: Docs rethinking payments as Sunshine Act looms.
    Lee J
    Mod Healthc; 2013 Jul; 43(26):12-3. PubMed ID: 23878901
    [No Abstract]   [Full Text] [Related]  

  • 5. French "sunshine act" sheds little light on drug industry's payments to doctors, say critics.
    Benkimoun P
    BMJ; 2013 Jun; 346():f3762. PubMed ID: 23757751
    [No Abstract]   [Full Text] [Related]  

  • 6. Two years of sunshine: has openness about payments reduced industry influence in healthcare?
    Lenzer J
    BMJ; 2016 Aug; 354():i4608. PubMed ID: 27562781
    [No Abstract]   [Full Text] [Related]  

  • 7. Plan to force drug companies in France to reveal payments to doctors has been diluted, campaigners say.
    Benkimoun P
    BMJ; 2012 Dec; 345():e8405. PubMed ID: 23236045
    [No Abstract]   [Full Text] [Related]  

  • 8. Sunlight as disinfectant--new rules on disclosure of industry payments to physicians.
    Rosenthal MB; Mello MM
    N Engl J Med; 2013 May; 368(22):2052-4. PubMed ID: 23718162
    [No Abstract]   [Full Text] [Related]  

  • 9. Brightening up: the effect of the Physician Payment Sunshine Act on existing regulation of pharmaceutical marketing.
    Gorlach I; Pham-Kanter G
    J Law Med Ethics; 2013; 41(1):315-22. PubMed ID: 23581674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Sunshine Act--effects on physicians.
    Agrawal S; Brennan N; Budetti P
    N Engl J Med; 2013 May; 368(22):2054-7. PubMed ID: 23718163
    [No Abstract]   [Full Text] [Related]  

  • 11. Transparency lacking. Despite Sunshine Act rules, policies still an issue.
    Lee J
    Mod Healthc; 2013 Mar; 43(10):10-1. PubMed ID: 23593894
    [No Abstract]   [Full Text] [Related]  

  • 12. Nothing to hide, something to gain? how the US Sunshine Act may effect Canadian doctors.
    Rivers J
    J Cutan Med Surg; 2012; 16(3):145-8. PubMed ID: 22930849
    [No Abstract]   [Full Text] [Related]  

  • 13. New US law applies 'sunshine' to physician payments and gifts from drug, device industries.
    Woodward C
    CMAJ; 2010 Jul; 182(10):E467-8. PubMed ID: 20501787
    [No Abstract]   [Full Text] [Related]  

  • 14. The Sunshine Act: it's for real now.
    Katayama AC
    WMJ; 2013 Apr; 112(2):96-7. PubMed ID: 23758019
    [No Abstract]   [Full Text] [Related]  

  • 15. Consultation starts on how to reveal payments from industry to doctors.
    Hawkes N
    BMJ; 2013 Jan; 346():f615. PubMed ID: 23360723
    [No Abstract]   [Full Text] [Related]  

  • 16. European drug agency's attempts to improve transparency stalled by legal action from two US drug companies.
    Dyer C
    BMJ; 2013 Jun; 346():f3588. PubMed ID: 23733481
    [No Abstract]   [Full Text] [Related]  

  • 17. GMC says it can't force doctors to disclose payments from drug companies.
    Torjesen I
    BMJ; 2016 Jul; 354():i3806. PubMed ID: 27390102
    [No Abstract]   [Full Text] [Related]  

  • 18. Doctors and drug companies--scrutinizing influential relationships.
    Campbell EG
    N Engl J Med; 2007 Nov; 357(18):1796-7. PubMed ID: 17978288
    [No Abstract]   [Full Text] [Related]  

  • 19. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
    Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
    Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Let the sunshine in--making industry payments to New Zealand doctors transparent.
    Farquhar C; Stokes T; Grey A; Jeffery M; Griffin P
    N Z Med J; 2015 Mar; 128(1411):6-12. PubMed ID: 25820497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.